1. |
O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth [J] . Cell, 1997; 88(2)∶277.
|
2. |
Davis DW, Shen Y, Mullani NA, et al. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors [J] . Clin Cancer Res, 2004; 10(1 Pt 1)∶33.
|
3. |
Capillo M, Mancuso P, Gobbi A, et al. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors [J] . Clin Cancer Res, 2003; 9(1)∶377.
|
4. |
賀祥, 潘衛, 黃耀誠, 等. 血管生成抑制素Endostatin研究新進展 [J] . 中國腫瘤生物治療雜志, 2000; 7(1)∶76.
|
5. |
楊林, 王金萬, 湯仲明, 等. 重組人血管內皮抑制素Ⅰ期臨床研究 [J] . 中國新藥研究, 2004; 13(6)∶538.
|
6. |
Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [J] . Nature, 1997; 390(6658)∶404.
|
7. |
Nyberg P, Heikkila P, Sorsa T, et al. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13 [J] . J Biol Chem, 2003; 278(25)∶22404.
|
8. |
劉然義, 易繼林, 邵俊偉, 等. 內皮抑素轉基因治療裸鼠人肝癌的實驗研究[J]. 中國普外基礎與臨床雜志, 2006; 13(2)∶145.
|
9. |
Hansma AH, Broxterman HJ, van der Horst I, et al. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase Ⅰ and pharmacokinetic study in patients with advanced cancer [J] . Ann Oncol, 2005; 16(10)∶1695.
|
10. |
Minning S, Serrano A, Ferrer P, et al. Optimization of the high-level production of Rhizopus oryzae lipase in Pichia pastoris [J] . J Biotechnol, 2001; 86(1)∶59.
|
11. |
Cereghino JL, Cregg JM. Heterologous protein expression in the methylotrophic yeast Pichia pastoris [J] . FEMS Microbiol Rev, 2000; 24(1)∶45.
|